SEC Form 4 · accession 0001209191-18-057930

GENOMIC HEALTH INC · GHDX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — COO

Period of report

Nov 7, 2018

Accepted (ET)

Nov 9, 2018 · 4:02 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001131324

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Nov 7, 2018	M	36,633	$27.00	A	72,171	D
Common Stock^F1	Nov 7, 2018	M	6,867	$27.48	A	79,038	D
Common Stock^F2,F3,F4,F1	Nov 7, 2018	S	2,100	$80.8571	D	76,938	D
Common Stock^F2,F3,F5,F1	Nov 7, 2018	S	700	$81.4368	D	76,238	D
Common Stock^F2,F3,F6,F1	Nov 7, 2018	S	3,657	$82.8731	D	72,581	D
Common Stock^F2,F3,F7,F1	Nov 7, 2018	S	700	$83.8629	D	71,881	D
Common Stock^F2,F3,F8,F1	Nov 7, 2018	S	13,916	$84.9995	D	57,965	D
Common Stock^F2,F3,F9,F1	Nov 7, 2018	S	18,477	$85.4928	D	39,488	D
Common Stock^F2,F3,F10,F1	Nov 7, 2018	S	3,781	$86.6086	D	35,707	D
Common Stock^F2,F11,F1	Nov 7, 2018	S	100	$88.59	D	35,607	D
Common Stock^F2,F11,F1	Nov 7, 2018	S	69	$89.60	D	35,538	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy) Holding^F12	$27.00	Nov 7, 2018	M	36,633	D	—	Feb 16, 2026	Common Stock	36,633	20,567	D
Employee Stock Option (right to buy) Holding^F13	$27.48	Nov 7, 2018	M	6,867	D	—	Jan 31, 2027	Common Stock	6,867	49,253	D

F1Includes an aggregate of 18,734 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
F10Represents weighted average sale price. Actual sale prices ranged from $86.50 to $86.87.
F11Represents actual sale price.
F12The option became exercisable as to 25% of the shares on February 16, 2017, and became exercisable as to 1/48th of the shares each full month thereafter.
F13The option became exercisable as to 25% of the shares on January 31, 2018, and becomes exercisable as to 1/48th of the shares each full month thereafter.
F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 7, 2018.
F3Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
F4Represents weighted average sale price. Actual sale prices ranged from $80.00 to $80.90.
F5Represents weighted average sale price. Actual sale prices ranged from $81.00 to $81.70.
F6Represents weighted average sale price. Actual sale prices ranged from $82.00 to $82.96.
F7Represents weighted average sale price. Actual sale prices ranged from $83.04 to $84.00.
F8Represents weighted average sale price. Actual sale prices ranged from $84.25 to $85.11.
F9Represents weighted average sale price. Actual sale prices ranged from $85.25 to $86.00.